Pluristem Therapeutc (PSTI) 1.47 $PSTI Pluristem

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pluristem Therapeutc (PSTI) 1.47 $PSTI

Pluristem Advances Towards Multinational Phase III Trial of PLX-PAD to Improve Recovery Following Surgery for Hip Fracture
GlobeNewswire - Wed Jul 27, 6:00AM CDT
-- Clinical Advisory Board of leading orthopedic specialists and experts in rehabilitation met to discuss the design of the Phase III study prior to submission of the protocol to the FDA
PSTI: 1.47 (-0.01)

Pluristem Advances its U.S. FDA Trial in Hematologic Indication
GlobeNewswire - Mon Jul 11, 6:30AM CDT
-- Enters into an agreement with a global drug development services company (CRO)
PSTI: 1.47 (-0.01)

Pluristem Therapeutics (PSTI) Catches Eye: Stock Up 11.6%
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:15AM CDT
Pluristem Therapeutics, Inc. (PSTI) shares rose almost 12% in the last trading session.
ANIP: 61.24 (+0.64), PSTI: 1.47 (-0.01)

Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
GlobeNewswire - Mon May 16, 2:00AM CDT
-- Trial expands to randomize 20 more patients to receive two injections per patient
PSTI: 1.47 (-0.01)

Pluristem Reports Third Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
GlobeNewswire - Tue May 10, 5:44AM CDT
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapy products, today reported financial highlights for its fiscal third quarter ended March 31, 2016, and provided clinical and corporate updates.
PSTI: 1.47 (-0.01)

Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke
GlobeNewswire - Thu Apr 21, 3:00AM CDT
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-derived cell therapy products, today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ischemic diseases with placental cell therapy rounding out the Company's IP coverage. This license follows Pluristem's recent announcement that the Japan Patent Office granted the Company two key patents addressing three-dimensional methods for expanding placental and adipose cells, and specified cell therapies produced from placental tissue using these methods.
PSTI: 1.47 (-0.01)

Intermittent Claudication - Pipeline Review, H1 2016 Featuring ID Pharma, Kowa Company, Nuo Therapeutics & Pluristem Therapeutics - Research and Markets
BusinessWire - Wed Mar 23, 1:31PM CDT
Research and Markets (http://www.researchandmarkets.com/research/hcbxlb/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H1 2016" report to their offering.
PSTI: 1.47 (-0.01)

Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
GlobeNewswire - Wed Feb 10, 6:59AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapy products, today reported financial highlights for its second quarter ended December 31, 2015, and provided clinical and corporate updates.
PSTI: 1.47 (-0.01)

Ian Massey, President and CEO of StemCells, Inc., to Participate on a Regenerative Medicine Panel at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference
GlobeNewswire - Thu Feb 04, 3:07PM CST
StemCells, Inc. (Nasdaq:STEM) announced today that Ian Massey, President and CEO of StemCells, Inc., will participate on a regenerative medicine panel at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference. The panel will take place on Feb. 10, at 1:30 p.m., Eastern Standard Time, at the Convene Conference Center, 730 3 Avenue, in New York City. The panel will be moderated by Todd Fromer, principal of KCSA Strategic Communications. Other panel members will include Adi Mohanty, Co-CEO, BioTime, Karine Kleinhaus, Div. VP, N.A., Pluristem Therapeutics, Dan Goldberger, CEO, Xtant Medical, and Mark Hedrick, MD, CEO, Cytori Therapeutics.
PSTI: 1.47 (-0.01), STEM: 0.38 (+0.01)

Pluristem's Placental Cells Prove Superior in Pre-Eclampsia a Leading Cause of Maternal and Fetal Death
ACCESSWIRE - Wed Feb 03, 8:00AM CST
FDA's Coveted Orphan Drug Designation Was Recently given to Pluristem in Pre-Eclampsia; Key Opinion Leader Dr. Brett Mitchell Comments on Clinical Results and Pluristem's Superiority
PSTI: 1.47 (-0.01)

Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.47 (-0.01), GSK: 45.23 (+0.16), CLBS: 6.05 (+0.51), MESO: 4.21 (+0.11), ATHX: 2.18 (-0.04), BXLT: 46.02 (-0.18)

Endonovo Therapeutics Tops Our List For Investor Potential in Biotechs
ACCESSWIRE - Thu Jan 28, 11:11AM CST
LAS VEGAS, NV / ACCESSWIRE / January 28, 2016 / Now that investors have gotten their first taste of the potential returns from the treatment of liver diseases, such as hepatitis C, which generated over $12.5 billion in 2014 sales and another $14.3 billion in the first nine months of 2015 for Gilead, companies are now looking to target other large liver disease markets.
INO: 10.27 (+0.39), PSTI: 1.47 (-0.01), GERN: 2.71 (+0.03), STEM: 0.38 (+0.01)

Pluristem to Commence Go-To-Market Pivotal Trial in 2016 for $12 Billion Critical Limb Ischemia Opportunity
ACCESSWIRE - Wed Jan 20, 10:02AM CST
Injection of PLX-PAD cell therapy to eliminate need for endovascular surgery
PSTI: 1.47 (-0.01)

Critical Limb Ischemia - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/htv6p6/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Critical Limb Ischemia Overview - Therapeutics Development - Pipeline Products for Critical Limb Ischemia - Overview - Pipeline Products for Critical Limb Ischemia - Comparative Analysis - Critical Limb Ischemia - Therapeutics under Development by Companies - Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes - Critical Limb Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Critical Limb Ischemia - Products under Development by Companies - Critical Limb Ischemia - Products under Investigation by Universities/Institutes - Critical Limb Ischemia - Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Caladrius Biosciences, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Multi Gene Vascular Systems Ltd - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group Plc - Stempeutics Research Private Limited - Targazyme, Inc. - TikoMed AB - U.S. Stem Cell, Inc. - Vericel Corporation - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...tical_limb
VCEL: 2.30 (+0.04), PSTI: 1.47 (-0.01), ATHX: 2.18 (-0.04), CLBS: 6.05 (+0.51)

Bone Marrow Transplantation Therapeutics Pipeline Report 2015
M2 - Wed Jan 20, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4wppsb/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bone Marrow Transplantation Overview - Therapeutics Development - Pipeline Products for Bone Marrow Transplantation - Overview - Pipeline Products for Bone Marrow Transplantation - Comparative Analysis - Bone Marrow Transplantation - Therapeutics under Development by Companies - Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes - Bone Marrow Transplantation - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bone Marrow Transplantation - Products under Development by Companies - Bone Marrow Transplantation - Products under Investigation by Universities/Institutes - Bone Marrow Transplantation - Companies Involved in Therapeutics Development - Anchor Therapeutics, Inc. - Boryung Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Compugen Ltd. - Mesoblast Limited - Pluristem Therapeutics Inc. - Proteonomix, Inc. - Taiga Biotechnologies, Inc. - Targazyme, Inc. For more information visit http://www.researchandmarkets.com/research/4w...one_marrow
MESO: 4.21 (+0.11), PSTI: 1.47 (-0.01), CGEN: 6.76 (+0.11), CBLI: 2.45 (-0.02)

Pluristem (PSTI) Gets FDA Approval for Phase I PLX-R18 Trial
Zacks Equity Research - Zacks Investment Research - Thu Jan 14, 2:35PM CST
Pluristem Therapeutics (PSTI) announced that the FDA has cleared its IND application to begin a phase I trial on PLX-R18 cells for treating incomplete hematopoietic recovery following hematopoietic cell transplantation.
GILD: 80.30 (+0.83), PSTI: 1.47 (-0.01), AZN: 33.90 (-0.24), ANIK: 51.80 (+1.88)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 53

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 292

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 49

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 26

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 150

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 135

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 32

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 69

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 67

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading

Top 5 Most Recently Viewed Articles

Labcon and Polycarbin Forge Sustainable Partnership for Labs

Updated Category News Views 93

Labcon Teams Up with Polycarbin for Sustainable Solutions Labcon North America, known for its commitment to Earth Friendly® laboratory disposables, is partnering with Polycarbin, a leader in sustainable laboratory solutions. This strategic alliance aims to promote a circular economy within the life sciences and pharmaceutical industries. Joining Forces for Circular...

Continue Reading
Toobit Innovates with New Card Payment for Cryptocurrency Purchases

Updated Category News Views 141

Toobit Introduces Hassle-free Cryptocurrency Purchases Toobit, a leading name in the cryptocurrency market, is breaking new ground by launching a feature that allows users to buy digital currencies using credit and debit cards. This innovative approach is set to simplify the purchasing process, enabling customers to engage in the world of cryptocurrencies with ease and...

Continue Reading
Exploring the UAE's Growing $40.8 Billion Wellness Landscape

Updated Category News Views 222

The UAE's Flourishing Wellness Economy In collaboration with key stakeholders, recent findings indicate that the wellness economy in the UAE has experienced impressive growth of 14.3% from 2019 to 2024. This demonstrates its status as the fastest-growing wellness market in the region. Valuation of the Wellness Sector The value of the wellness industry in the UAE has...

Continue Reading
Waylens Partners with Greater Than for Enhanced Fleet Safety

Updated Category News Views 165

Waylens and Greater Than Join Forces for Fleet Safety In an exciting development for the fleet management industry, Waylens, recognized for its cutting-edge AI video telematics technology, is partnering with Greater Than, a leading provider of risk intelligence focused on road safety and climate impacts. This collaboration aims to enhance fleet safety by integrating video...

Continue Reading
Heavy Options Trading Indicates Optimism for NuScale Power

Updated Category News Views 185

NuScale Power Sees Significant Options Activity Investors are increasingly showing a positive outlook towards NuScale Power (NYSE: SMR), an engagement worth noting in the market landscape. Recent tracking of public options records has revealed notable movements among deep-pocketed investors today. Understanding the Options Landscape Today, the options scanner brought to...

Continue Reading